Advertisement

Aromatase Inhibitors as Chemopreventives of Breast Cancer

  • Mitchell Dowsett
  • Judy E. Garber
Chapter
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

Aromatase is a cytochrome P450 enzyme present in the endoplasmic reticulum (ER) which is responsible for the synthesis of steroidal estrogens. It appears that a single aromatase gene codes for the enzyme in all tissues, but, as discussed here, the control of this gene is tissue-specific according to the usage of a number of different promoters (1). Aromatase catalyzes the conversion of androstenedione (the preferred substrate) and testosterone to estrone, then to estradiol. The conversion of estrone to estradiol the most potent estrogen is reversible, and is catalyzed by the 17(β hydroxysteroiddehydrogenase enzyme system (Fig. 1).

Keywords

Breast Cancer Breast Cancer Risk Aromatase Inhibitor Advanced Breast Cancer Mammographic Density 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Simpson ER, Dowsett M. Aromatase and its inhibitors: significance for breast cancer therapy. Recent Prog Horm Res 2002;57:317–338.PubMedCrossRefGoogle Scholar
  2. 2.
    Santen RJ, Samojlik E, Wells SA. Resistance of the ovary to blockade of aromatization with aminoglutethimide. J Clin Endocrinol Metab 1980;51:473–477.PubMedCrossRefGoogle Scholar
  3. 3.
    Harris AL, Dowsett M, Jeffcoate SL, et al. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. J Clin Endocrinol Metab 1982;55:718–722.PubMedCrossRefGoogle Scholar
  4. 4.
    Stein RC, Dowsett M, Hedley A, et al. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br J Cancer 1990;62:679–683.PubMedCrossRefGoogle Scholar
  5. 5.
    Sinha S, Kaseta J, Santner SJ, et al. Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat. Breast Cancer Res Treat 1998;48:45–51.PubMedCrossRefGoogle Scholar
  6. 6.
    Shetty G, Krishnamurthy H, Krishnamurthy HN, et al. Effect of estrogen deprivation on the reproductive physiology of male and female primates. J Steroid Biochem Mol Biol 1997;61:157–166.PubMedCrossRefGoogle Scholar
  7. 7.
    Mitwally MF, Casper RF. Aromatase inhibition for ovarian stimulation: future avenues for infertility management. Curr Opin Obstet Gynecol 2002;14:255–263.PubMedCrossRefGoogle Scholar
  8. 8.
    Longcope C, Baker R, Johnston CC Jr. Androgen and estrogen metabolism: relationship to obesity. Metabolism 1986;35:235–237.PubMedCrossRefGoogle Scholar
  9. 9.
    Hemsell DL, Grodin JM, Brenner PF, et al. Plasma precursors of estrogen. II Correlation of the extent of conversion of androstenedione to estrone with age. J Clin Endocrinol Metab 1974;38:476–479.PubMedCrossRefGoogle Scholar
  10. 10.
    Miller WR, Dixon JM. Local endocrine effects of aromatase inhibitors within the breast. J Steroid Biochem Mol Biol 2001;79:93–102.PubMedCrossRefGoogle Scholar
  11. 11.
    Miller WR. Importance of intratumoural aromatase and its susceptibility to inhibitors, in Aromatase Inhibition-Then, Now and Tomorrow. Dowsett M, ed., Partenon Publishing, London 1994, pp. 43–53.Google Scholar
  12. 12.
    Silva MC, Rowlands MG, Dowsett M, et al. Intratumoral aromatase as a prognostic factor in human breast carcinoma. Cancer Res 1989;49:2588–2591.PubMedGoogle Scholar
  13. 13.
    Lipton A, Santen RJ, Santner SJ, et al. Prognostic value of breast cancer aromatase. Cancer 1992;70:1951–1955.PubMedCrossRefGoogle Scholar
  14. 14.
    Miller WR, Mullen P, Telford J, Dixon JM. Clinical importance of intratumoral aromatase. Breast Cancer Res Treat 1998;49 Suppl 1:S27-S32.Google Scholar
  15. 15.
    Feigelson HS, Henderson BE. Estrogens and breast cancer. Carcinogenesis 1996;17:2279–2284.PubMedCrossRefGoogle Scholar
  16. 16.
    Endogenous Hormones and Breast Cancer Collaborative Group (EHBCCG). Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606–616.CrossRefGoogle Scholar
  17. 17.
    Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637–645.PubMedCrossRefGoogle Scholar
  18. 18.
    Liehr JG. Genotoxicity of the steroidal oestrogens oestrone and oestradiol: possible mechanism of uterine and mammary cancer development. Hum Reprod Update 2001;7:273–281.PubMedCrossRefGoogle Scholar
  19. 19.
    Stuart-Harris RC, Smith IE. Aminoglutethimide in the treatment of advanced breast cancer. Cancer Treat Rev 1984;11:189–204.PubMedCrossRefGoogle Scholar
  20. 20.
    Brodie A, Long B. Aromatase inhibition and inactivation. Clin Cancer Res 2001;12 Supp1:4343s-4349s.Google Scholar
  21. 21.
    Di Salle E, Giudici D, Ornati G, et al. 4-Aminoandrostenedione derivatives: a novel class of irreversible aromatase inhibitors. Comparison with FCE 24304 and 4-hydroxyandrostenedione. J Steroid Biochem Mol Biol 1990;37:369–374.PubMedCrossRefGoogle Scholar
  22. 22.
    Dowsett M, Cunningham DC, Stein RC, et al. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res 1989;49:1306–1312.PubMedGoogle Scholar
  23. 23.
    Johannessen DC, Engan T, Di Salle E, et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a Phase I study. Clin Cancer Res 1997;3:1101–1108.PubMedGoogle Scholar
  24. 24.
    Kao YC, Cam LL, Laughton CA, Zhou D, Chen S. Binding characteristics of seven inhibitors of human aromatase: a site-directed mutagenesis study. Cancer Res 1996;56:3451–3460.PubMedGoogle Scholar
  25. 25.
    Miller WR, Dixon JM. Antiaromatase agents: preclinical data and neoadjuvant therapy. Clin Breast Cancer 2000;1 Suppl 1:S9-S14.PubMedCrossRefGoogle Scholar
  26. 26.
    Wing LY, Garrett WM, Brodie AM. Effects of aromatase inhibitors, aminoglutethimide, and 4-hydroxyandrostenedione on cyclic rats and rats with 7, 12dimethylbenz(a)anthracene-induced mammary tumors. Cancer Res 1985;45:2425–2428.PubMedGoogle Scholar
  27. 27.
    Wilkinson JR, Williams JC, Singh D, et al. Response of nitrosomethylurea-induced rat mammary tumor to endocrine therapy and comparison with clinical response. Cancer Res 1986;46:4862–4865.PubMedGoogle Scholar
  28. 28.
    Schieweck K, Bhatnagar AS, Batzl C, Lang M. Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors. J Steroid Biochem Mol Biol 1993;44:633–636.PubMedCrossRefGoogle Scholar
  29. 29.
    Lu Q, Yue W, Wang J, et al. The effects of aromatase inhibitors and antiestrogens in the nude mouse model. Breast Cancer Res Treat 1998;50:63–71.PubMedCrossRefGoogle Scholar
  30. 30.
    Lee K, Macaulay VM, Nicholls JE, et al. An in vivo model of intratumoural aromatase using aromatase-transfected MCF7 human breast cancer cells. Int J Cancer 1995;62:297–302.PubMedCrossRefGoogle Scholar
  31. 31.
    Dukes M. The relevance of preclinical models to the treatment of postmenopausal breast cancer. Oncology 1997;54 Suppl 2:6–10.PubMedCrossRefGoogle Scholar
  32. 32.
    Liu XD, Xie L, Zhong Y, Li CX. Gender difference in letrozole pharmacokinetics in rats. Acta Pharmacol Sinica 2000;2:680–684.Google Scholar
  33. 33.
    Lubet RA, Steele VE, DeCoster R, et al. Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model. Carcinogenesis 1998;19:1345–1351.PubMedCrossRefGoogle Scholar
  34. 34.
    Gunson DE, Steele RE, Chau RY. Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor. Br J Cancer 1995;72:72–75.PubMedCrossRefGoogle Scholar
  35. 35.
    Gunson DE, Bell R, Sahota PS, Hsu HH. Inhibition of spontaneous mammary tumors by CGS 20267, an aromatase inhibitor, in female Sprague-Dawley rats. Toxicol Pathol 1996;24:789.Google Scholar
  36. 36.
    Tekmal RR, Ramachandra N, Gubba S, et al. Overexpression of int-5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities. Cancer Res 1996;56:3180–3185.PubMedGoogle Scholar
  37. 37.
    Mandava U, Kirma N, Tekmal RR. Aromatase overexpression transgenic mice model: cell type specific expression and use of letrozole to abrogate mammary hyperplasia without affect-ing normal physiology. J Steroid Biochem Mol Biol 2001;79:27–34.PubMedCrossRefGoogle Scholar
  38. 38.
    Feinlieb M. Breast cancer and artificial menopause: a cohort study. J Natl Cancer Inst 1968;41:315–329.Google Scholar
  39. 39.
    Nissen-Meyer R. Primary breast cancer: the effect of primary ovarian irradiation. Ann Oncol 1991;2:343–346.PubMedGoogle Scholar
  40. 40.
    Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453–461.PubMedGoogle Scholar
  41. 41.
    Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a Phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000;18:1399–1411.PubMedGoogle Scholar
  42. 42.
    Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two Phase III trials. Arimidex Study Group. J Clin Oncol 1996;14:2000–2011.PubMedGoogle Scholar
  43. 43.
    Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001;19:3357–3366.PubMedGoogle Scholar
  44. 44.
    Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92:2247–2258.PubMedCrossRefGoogle Scholar
  45. 45.
    Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596–2606.PubMedGoogle Scholar
  46. 46.
    Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001;12:1527–1532.PubMedCrossRefGoogle Scholar
  47. 47.
    ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131–2139.CrossRefGoogle Scholar
  48. 48.
    EBCTCG. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998;351:1451–1467.CrossRefGoogle Scholar
  49. 49.
    Peto J, Mack TM. High constant incidence in twins and other relatives of women with breast cancer. Nat Genet 2000;26:411–414.PubMedCrossRefGoogle Scholar
  50. 50.
    MacNeill FA, Jones AL, Jacobs S, et al. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br J Cancer 1992;66:692–697.PubMedCrossRefGoogle Scholar
  51. 51.
    Geisler J, Haynes B, Anker G, et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002;20:751–757.PubMedCrossRefGoogle Scholar
  52. 52.
    Geisler J, King N, Anker G, et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998;4:2089–2093.PubMedGoogle Scholar
  53. 53.
    ATAC Trialists’ Group. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex and tamoxifen alone or in combination’ (ATAC) trial. Br J Cancer 2001;85:317–324.CrossRefGoogle Scholar
  54. 54.
    Dowsett M, Pfister C, Johnston SR, et al. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clin Cancer Res 1999;5:2338–2343.PubMedGoogle Scholar
  55. 55.
    Stuart-Harris RC, Smith IE. Aminoglutethimide in the treatment of advanced breast cancer. Cancer Treat Rev 1984;11:189–204.PubMedCrossRefGoogle Scholar
  56. 56.
    Plourde PV, Dyroff M, Dowsett M, et al. ARIMIDEX: a new oral, once-a-day aromatase inhibitor. J Steroid Biochem Mol Biol 1995;53:175–179.PubMedCrossRefGoogle Scholar
  57. 57.
    Bajetta E, Zilembo N, Dowsett M, et al. Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur J Cancer 1999;35:208–213.PubMedCrossRefGoogle Scholar
  58. 58.
    Harper-Wynne C, Ross G, Sacks N, et al. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol. Biomark Prey 2002;11:614–621.Google Scholar
  59. 59.
    Engan T, Krane J, Johannessen DC, et al. Plasma changes in breast cancer patients during endocrine therapy lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Res Treat 1995;36:287–297.PubMedCrossRefGoogle Scholar
  60. 60.
    Elisaf MS, Bairaktari ET, Nicolaides C, et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 2001;37:1510–1513.PubMedCrossRefGoogle Scholar
  61. 61.
    Harper-Wynne CL, Sacks NP, et al. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol 2002b;20:1026–1035.CrossRefGoogle Scholar
  62. 62.
    Heshmati HM, Khosla S, Robins SP, et al. Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Mineral Res 2002;17:172–178.CrossRefGoogle Scholar
  63. 63.
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371–1388.PubMedCrossRefGoogle Scholar
  64. 64.
    Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and post-menopausal women. J Clin Oncol 1996;14:78–84.PubMedGoogle Scholar
  65. 65.
    Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet 1996;348:429–432.PubMedCrossRefGoogle Scholar
  66. 66.
    Harper-Wynne C, Dowsett M. Recent advances in the clinical application of aromatase inhibitors. J Steroid Biochem Mol Biol 2001;760:179–186.CrossRefGoogle Scholar
  67. 67.
    Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529–1542.PubMedCrossRefGoogle Scholar
  68. 68.
    Stewart HJ, Prescott RJ, Forrest AP. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001;93:456–462.PubMedCrossRefGoogle Scholar
  69. 69.
    Tarone RE, Chu KC. The greater impact of menopause on ER- than ER+ breast cancer incidence: a possible explanation (United States). Cancer Causes Control 2002;13:7–14.PubMedCrossRefGoogle Scholar
  70. 70.
    Huang WY, Newman B, Millikan RC, et al. Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol 2000;151:703–714.PubMedCrossRefGoogle Scholar
  71. 71.
    Ursin G, Tseng CC, Paganini-Hill A, et al. Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer? J Clin Oncol 2002;20:699–706.PubMedCrossRefGoogle Scholar
  72. 72.
    Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879–1886.PubMedCrossRefGoogle Scholar
  73. 73.
    Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999;91:1541–1548.PubMedCrossRefGoogle Scholar
  74. 74.
    Spiegelman D, Colditz GA, Hunter D, Hertzmark E. Validation of the Gail et al. model for predicting individual breast cancer risk. J Natl Cancer Inst 1994;86:600–607.PubMedCrossRefGoogle Scholar
  75. 75.
    Rockhill B, Spiegelman D, Byrne C, et al. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 2001;93:358–366.PubMedCrossRefGoogle Scholar
  76. 76.
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371–1388.PubMedCrossRefGoogle Scholar
  77. 77.
    Shaaban AM, Sloane JP, West CR, Foster CS. Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression. Am J Pathol 2002;160:597–604.PubMedCrossRefGoogle Scholar
  78. 78.
    Shoker BS, Jarvis C, Sibson DR, et al. Oestrogen receptor expression in the normal and pre-cancerous breast. J Pathol 1999;188:237–244.PubMedCrossRefGoogle Scholar
  79. 79.
    Rutter CM, Mandelson MT, Laya MB, et al. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA 2001;285:171–176.PubMedCrossRefGoogle Scholar
  80. 80.
    Chow CK, Venzon D, Jones EC, et al. Effect of tamoxifen on mammographic density. Cancer Epidemiol Biomark Prey 2000;9:917–921.Google Scholar
  81. 81.
    Byrne C, Schairer C, Wolfe J, et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Nall Cancer Inst 1995;87:1622–1629.CrossRefGoogle Scholar
  82. 82.
    Boyd NF, Byng JW, Jong RA, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995;87:670–675.PubMedCrossRefGoogle Scholar
  83. 83.
    Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Nall Cancer Inst 1998;90:1292–1299.CrossRefGoogle Scholar
  84. 84.
    Kristensen VN, Harada N, Yoshimura N, et al. Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene 2000;19:1329–1333.PubMedCrossRefGoogle Scholar
  85. 85.
    Haiman CA, Hankinson SE, Spiegelman D, et al. No association between a single nucleotide polymorphism in CYP19 and breast cancer risk. Cancer Epidemiol Biomarkers Prey 2002;11:215–216.Google Scholar
  86. 86.
    Day R, Ganz PA, Costantino JP, et al. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 1999;17:2659–2669.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Mitchell Dowsett
  • Judy E. Garber

There are no affiliations available

Personalised recommendations